Rafal Swiercz, Ph.D.
Affiliations: | 2001 | Medical College of Ohio, Toledo, OH, United States |
Area:
Molecular BiologyGoogle:
"Rafal Swiercz"Parents
Sign in to add mentor| Jerzy Jankun | grad student | 2001 | Medical College of Ohio | |
| (Evaluation of 14-1B mutant of recombinant human plasminogen activator inhibitor type 1 (PAI-1) as a potential anti-angiogenic and anti-cancer agent.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Kantara C, Sarkar S, Swiercz R, et al. (2011) Abstract 4363: Inhibitory efficacy of curcumin ± stem cell specific RNAi on the growth of tumorospheres in vitro: Assay development and mechanisms of action Cancer Research. 71: 4363-4363 |
| Kantara C, Sarkar S, Swiercz R, et al. (2011) Overexpression of Progastrin Imparts Tumorigenic/Metastatic Potential to Immortalized Embryonic Cells and Cancer Cells: Role of Stem/Progenitor Cell Markers and AnnexinA2 Gastroenterology. 140: S-48 |
| Chorostowska-Wynimko J, Swiercz R, Skrzypczak-Jankun E, et al. (2005) P-022 Plasminogen activator inhibitor type-1 regulates the lungcapilaries endothelial cells (HMVEC-L) angiogenic activity via urokinase-dependent pathway Lung Cancer. 49: S121 |
| Chorostowska-Wynimko J, Swiercz R, Skrzypczak-Jankun E, et al. (2004) Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells. Oncology Reports. 12: 1155-62 |
| Chorostowska-Wynimko J, Swiercz R, Skrzypczak-Jankun E, et al. (2003) A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis. Molecular Cancer Therapeutics. 2: 19-28 |
| Swiercz R, Keck RW, Skrzypczak-Jankun E, et al. (2001) Recombinant PAI-1 inhibits angiogenesis and reduces size of LNCaP prostate cancer xenografts in SCID mice. Oncology Reports. 8: 463-70 |
| Swiercz R, Skrzypczak-Jankun E, Merrell MM, et al. (1999) Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator. Oncology Reports. 6: 523-6 |
| Swiercz R, Wolfe JD, Zaher A, et al. (1998) Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype Clinical Cancer Research. 4: 869-877 |
| Jankun J, Selman SH, Swiercz R, et al. (1997) Why drinking green tea could prevent cancer. Nature. 387: 561 |
| Jankun J, Keck RW, Skrzypczak-Jankun E, et al. (1997) Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice. Cancer Research. 57: 559-63 |